SeaStar Medical Holding Corporation (NASDAQ:ICU) Short Interest Update

SeaStar Medical Holding Corporation (NASDAQ:ICU) was the target of a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 138,925 shares, a growth of 69.6% from the June 30th total of 81,907 shares. Currently, 3.5% of the shares of the stock are short sold. Based on an average daily volume of 149,755 shares, the days-to-cover ratio is presently 0.9 days.

SeaStar Medical Stock Down 2.2%

Shares of SeaStar Medical stock opened at $3.18 on Friday. The firm has a market cap of $12.72 million, a price-to-earnings ratio of -0.66 and a beta of -1.05. The business has a fifty day simple moving average of $3.71 and a 200-day simple moving average of $3.36. SeaStar Medical has a fifty-two week low of $2.07 and a fifty-two week high of $12.50.

SeaStar Medical (NASDAQ:ICU) last released its earnings results on Wednesday, May 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). SeaStar Medical had a negative return on equity of 146.29% and a negative net margin of 828.62%.The firm had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.44 million. Analysts anticipate that SeaStar Medical will post -3.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SeaStar Medical

A number of institutional investors have recently bought and sold shares of ICU. Millennium Management LLC purchased a new position in SeaStar Medical during the 3rd quarter valued at about $102,000. Jane Street Group LLC purchased a new stake in shares of SeaStar Medical in the fourth quarter worth approximately $30,000. Finally, XTX Topco Ltd lifted its position in shares of SeaStar Medical by 395.4% in the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after purchasing an additional 48,674 shares in the last quarter. 1.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Maxim Group set a $8.00 target price on shares of SeaStar Medical and gave the company a “buy” rating in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. Finally, Wall Street Zen cut shares of SeaStar Medical from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.00.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.